XML 44 R35.htm IDEA: XBRL DOCUMENT v3.23.2
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Biogen MA, Inc. (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
May 31, 2020
USD ($)
Apr. 30, 2020
USD ($)
product_target
$ / shares
shares
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2020
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Number of additional neurological disease gene targets (in product targets) | product_target   7            
Accounts receivable     $ 2,716   $ 2,716   $ 3,678  
General and administrative expense     16,014 $ 15,093 34,150 $ 30,001    
Biogen MA, Inc.                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Change in estimate of transaction price, increase in revenue         127,100      
Biogen MA, Inc. | License and Service                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Fixed consideration   $ 204,600            
Remaining performance obligation amount     0   0   151,300  
General and administrative expense     30 $ 100 2,600 $ 300    
Biogen MA, Inc. | Stock Purchase Agreement                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Sale of stock, number of shares issued in transaction (in shares) | shares   24,420,157            
Sale of stock, price per share (in dollars per share) | $ / shares   $ 9.2137            
Consideration received on transaction   $ 225,000            
Sale of stock, excess consideration received on transaction   79,600            
Collaboration agreement, equity issued   145,400            
Accounts receivable     400   400   500  
Deferred revenue     0   0   $ 132,200  
Biogen MA, Inc. | Collaboration And License Agreement                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Proceeds from collaborators $ 125,000 $ 125,000            
Number of neurological disease gene targets selected by counterparty (in product targets) | product_target   4            
Financial advisory fees               $ 7,000
Percent of initial recognition   2.00%            
Contract with customer, asset, after allowance for credit Loss     $ 4,100   $ 4,100